1. Introduction: Multidrug-resistant tuberculosis: past, present and future; I. Bastian, F. Portaels. 2. The epidemiology of multidrug-resistant tuberculosis in the United States and other established market economies; M. Moore, E. McCray, I.M. Onorato. 3. Epidemiology of multidrug-resistant tuberculosis in low- and middle-income countries; M.A. Espinal. 4. The interaction of human immunodeficiency virus and multidrug-resistant tuberculosis; E. McCray, I.M. Onorato. 5. Clinical mismanagement and other factors producing antituberculosis drug resistance; A. Pablos-Mendez, K. Lessnau. 6. The molecular mechanisms of drug resistance in mycobacterium tuberculosis; H.E. Takiff. 7. DOTS and multidrug-resistant tuberculosis; M.C. Raviglione. 8.Conventional methods for antimicrobial susceptibility testing of mycobacterium tuberculosis; L. Heifets. 9. Novel rapid antimicrobial susceptibility tests for mycobacterium tuberculosis; J.C. Palomino. 10. Pharmacology of the second-line antituberculosis drugs; C.A. Peloquin, B. Auclair. 11. Treatment of multidrug-resistant tuberculosis; M.D. Iseman, G.A. Huitt. 12. Treatment of multidrug resistant tuberculosis in developing countries; J. Crofton, A. van Deun. 13. Treatment outcome of multidrug-resistant tuberculosis; E.E. Telzak. 14. Chemoprophylaxis and BCG in contacts of multidrug resistant tuberculosis; R.A. Stapledon, R. Lumb, I.S. Lim. 15. Multidrug-resistant tuberculosis and the health care worker; D.M. Weinstock, K.A. Sepkowitz. 16. The development of new chemotherapeutics for multidrug-resistant tuberculosis; C.E. Barry. 17. Population dynamics and control of multidrug-resistant tuberculosis; C. Dye, B.G. Williams. 18. Administrative, engineering, and personal protective measures for controlling mycobacterium tuberculosis; C. Richards, W.R. Jarvis. 19. Making DOTS plus work; P.E. Farmer, S.S. Shin, J. Bayona, J.Y. Kim, J.J. Furin, J.G. Brenner.